Phaseline

Companies › Novelwise Pharmaceutical

Novelwise Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NBM-BMX
HDAC8 inhibitor
HDAC (class I/II)Phase 1Metastatic Uveal Melanoma; Malignant Neoplasm; Malignant Neoplasm of BrainMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07136181NBM-BMXPhase 1Metastatic Uveal MelanomaOncologyMar 2028
NCT06012695NBM-BMXPhase 1Malignant NeoplasmOncologyMay 2028
NCT07569042NBM-BMXPhase 1Malignant Neoplasm of BrainOncologySep 2029

Targets

HDAC (class I/II) (1)

Companies with the same targets

Xynomic Pharmaceuticals Jubilant Therapeutics Unravel Biosciences Great Novel Therapeutics Biotech & Medicals Italfarmaco Daiichi Sankyo Chengdu Zenitar Biomedical Technology Acrotech Biopharma Chipscreen Biosciences Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.